ストックスクリーナーアプリを入手
1.93
2.66%
0.05
アフターアワーズ：
1.93
前日終値:
$1.88
開ける：
$1.87
24時間の取引高:
86,821
Relative Volume:
0.36
時価総額：
$143.48M
収益：
-
当期純損益:
$-19.57M
株価収益率:
-0.6166
EPS:
-3.13
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
+7.22%
1か月 パフォーマンス:
+16.27%
6か月 パフォーマンス:
-31.07%
1年 パフォーマンス:
+30.41%
1日の値動き範囲:
$1.87
$1.94
1週間の範囲:
$1.76
$1.94
52週間の値動き範囲:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
678-392-3419
住所
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.93 | 133.81M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Is Inhibikase Therapeutics Inc. a good long term investmentRecord-breaking capital gains - jammulinksnews.com
What drives Inhibikase Therapeutics Inc. stock priceTremendous growth opportunities - jammulinksnews.com
Inhibikase Therapeutics Inc. Stock Analysis and ForecastHigh-impact investment strategies - jammulinksnews.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyVolume Spike Monitors - Newser
What analysts say about Inhibikase Therapeutics Inc. stockTremendous return on equity - jammulinksnews.com
What risks could impact Inhibikase Therapeutics Inc. stock performance2x Return Forecast - Newser
Why Inhibikase Therapeutics Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - beatles.ru
How Inhibikase Therapeutics Inc. stock performs during market volatilityFree Step-by-Step Investment Guide - beatles.ru
Inhibikase Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Inhibikase Therapeutics shareholders elect directors and approve equity plan changes - Investing.com India
Inhibikase Therapeutics Soars 6.79% on Russell 2000 Index Addition - AInvest
Inhibikase Therapeutics, Inc.(NasdaqCM: IKT) added to Russell 2500 Index - MarketScreener
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director By Investing.com - Investing.com UK
Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan
Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Former Inhibikase leader launches new biotech for midstage Parkinson's asset - Fierce Biotech
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
Inhibikase Therapeutics Inc (IKT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
0.51%
大文字化:
|
ボリューム (24 時間):